Ptc Therapeutics (PTCT) Capital Expenditures (2012 - 2026)

Ptc Therapeutics' Capital Expenditures history runs 15 years deep, the most recent figure standing at $2.2 million for Q2 2026.

• In Q2 2026, Capital Expenditures rose 75.78% year-over-year to $2.2 million; the TTM figure through Jun 2026 stood at $9.3 million (up 27.8% YoY), while the FY2025 annual figure was $8.9 million, up 36.27% from the prior year.
• Capital Expenditures for Q2 2026 stood at $2.2 million, up from $1.2 million in the prior quarter.
• The five-year high for Capital Expenditures was $10.3 million in Q1 2023, with the low at -$7.4 million in Q2 2024.
• The 5-year median for Capital Expenditures is $4.6 million (2022), against an average of $4.4 million.
• The sharpest annual moves came in 2024 and 2025: Capital Expenditures slumped 218.09% in 2024, then jumped 573.37% in 2025.
• Ptc Therapeutics' Capital Expenditures stood at $8.6 million in 2022, then slumped by 35.44% to $5.6 million in 2023, then sank by 32.32% to $3.8 million in 2024, then tumbled by 36.98% to $2.4 million in 2025, then decreased by 7.67% to $2.2 million in 2026.
• Business Quant data shows PTCT's Capital Expenditures at $2.2 million in Q2 2026, $1.2 million in Q1 2026, and $2.4 million in Q4 2025.